A role of chemotherapy for malignant peripheral nerve sheath tumors (MPNSTs): A retrospective analysis of 40 cases in a single institution.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. e20512-e20512 ◽  
Author(s):  
Y. Funakoshi ◽  
A. Kawai ◽  
A. Hosono ◽  
A. Yoshida ◽  
H. Chuuman ◽  
...  
2020 ◽  
Vol 36 (10) ◽  
pp. 2453-2462
Author(s):  
Enrico Martin ◽  
Uta E. Flucke ◽  
J. Henk Coert ◽  
Max M. van Noesel

Abstract Background Malignant peripheral nerve sheath tumors (MPNSTs) are rare yet highly aggressive soft tissue sarcomas. Children with neurofibromatosis type 1 (NF1) have a 10% lifetime risk for development of MPNST. Prognosis remains poor and survival seems worse for NF1 patients. Methods This narrative review highlights current practices and pitfalls in the management of MPNST in pediatric NF1 patients. Results Preoperative diagnostics can be challenging, but PET scans have shown to be useful tools. More recently, functional MRI holds promise as well. Surgery remains the mainstay treatment for these patients, but careful planning is needed to minimize postoperative morbidity. Functional reconstructions can play a role in improving functional status. Radiotherapy can be administered to enhance local control in selected cases, but care should be taken to minimize radiation effects as well as reduce the risk of secondary malignancies. The exact role of chemotherapy has yet to be determined. Reports on the efficacy of chemotherapy vary as some report lower effects in NF1 populations. Promisingly, survival seems to ameliorate in the last few decades and response rates of chemotherapy may increase in NF1 populations when administering it as part of standard of care. However, in metastasized disease, response rates remain poor. New systemic therapies are therefore desperately warranted and multiple trials are currently investigating the role of drugs. Targeted drugs are nevertheless not yet included in first line treatment. Conclusion Both research and clinical efforts benefit from multidisciplinary approaches with international collaborations in this rare malignancy.


2012 ◽  
Vol 24 (3) ◽  
pp. 308-310 ◽  
Author(s):  
Alexandros Chatzistefanou ◽  
Michalis Mantatzis ◽  
Savas Deftereos ◽  
Paraskevi Mintzopoulou ◽  
Panos Prassopoulos

2019 ◽  
Vol 21 (11) ◽  
pp. 1389-1400 ◽  
Author(s):  
Tsung-Chieh Shih ◽  
Yunpeng Fan ◽  
Sophie Kiss ◽  
Xiaocen Li ◽  
Xiaojun Nicole Deng ◽  
...  

Abstract Background The Ras signaling pathway is commonly dysregulated in human malignant peripheral nerve sheath tumors (MPNSTs). It is well known that galectin-1 (Gal-1) is essential to stabilize membrane Ras and thereby induce the activation of Ras. However, the role of Gal-1 in MPNST progression remains unknown. The aim of this study was to examine whether Gal-1 knockdown could have an effect on the Ras signaling pathway. Methods Cell viability, apoptosis assay, and colony formation were performed to examine the effects of inhibition of Gal-1 in MPNST cells. We used a human MPNST xenograft model to assess growth and metastasis inhibitory effects of Gal-1 inhibitor LLS2. Results Gal-1 was upregulated in MPNST patients and was highly expressed in MPNST cells. Knockdown of Gal-1 by small interfering (si)RNA in Gal-1 expressing MPNST cells significantly reduces cell proliferation through the suppression of C-X-C chemokine receptor type 4 (CXCR4) and the rat sarcoma viral oncogene homolog (RAS)/extracellular signal-regulated kinase (ERK) pathway, which are important oncogenic signaling in MPNST development. Moreover, Gal-1 knockdown induces apoptosis and inhibits colony formation. LLS2, a novel Gal-1 allosteric small molecule inhibitor, is cytotoxic against MPNST cells and was able to induce apoptosis and suppress colony formation in MPNST cells. LLS2 treatment and Gal-1 knockdown exhibited similar effects on the suppression of CXCR4 and RAS/ERK pathways. More importantly, inhibition of Gal-1 expression or function by treatment with either siRNA or LLS2 resulted in significant tumor responses in an MPNST xenograft model. Conclusion Our results identified an oncogenic role of Gal-1 in MPNST and that its inhibitor, LLS2, is a potential therapeutic agent, applied topically or systemically, against MPNST.


2009 ◽  
Vol 23 (1) ◽  
pp. 43-48 ◽  
Author(s):  
Juliana Tito Salla ◽  
Aline Cristina Batista Rodrigues Johann ◽  
Bruna Gonçalves Garcia ◽  
Maria Cássia Ferreira Aguiar ◽  
Ricardo Alves Mesquita

2020 ◽  
Vol 41 (9) ◽  
pp. 924-932
Author(s):  
Divya Yadav ◽  
Shamim Ahmed Shamim ◽  
Sameer Rastogi ◽  
D.M. Rituraj Upadhyay ◽  
Anil Kumar Pandey ◽  
...  

2008 ◽  
Vol 8 (2) ◽  
pp. 129-134 ◽  
Author(s):  
Atul Goel ◽  
Dattatraya Muzumdar ◽  
Trimurti Nadkarni ◽  
Ketan Desai ◽  
Nitin Dange ◽  
...  

Object This study is a retrospective analysis of 60 surgically treated patients with 64 peripheral nerve sheath tumors (PNSTs) at the second cervical (C-2) nerve root. The anatomical subtleties of these tumors and their implications for surgical strategy when compared with other spinal PNSTs and other tumors in the foramen magnum region are reviewed. Methods Sixty patients with C-2 PNSTs treated surgically in the Department of Neurosurgery at King Edward VII Memorial Hospital and Seth Gordhandas Sunderdas Medical College between 1992 and 2006 were studied. All patients underwent magnetic resonance imaging. Tumors were divided into 3 groups depending on their anatomical location identified during surgery. Those tumors located within or extending into the spinal dural tube were called Type A, those located within the dural tube of the C-2 ganglion were labeled as Type B, and tumors extending laterally into the paraspinal region were labeled as Type C. Follow-up durations ranged from 6 months to 15 years (mean 64 months). Results There were 38 male and 22 female patients in the study, who ranged in age from 6 to 62 years (mean 28 years). Nine patients had clinical features indicative of neurofibromatosis (NF). The mean duration of symptoms at the time of presentation was 27 months (range 4 days–5 years). Two patients had no specific symptoms related to the C-2 PNST, 6 patients had only local symptoms such as neck pain or stiffness, and 52 patients had symptoms of varying degrees of myelopathy. There were 5 solely Type A tumors, 7 Type A + B tumors, 31 Type B tumors, and 21 Type B + C tumors. All Type A, A + B, and B tumors were totally resected. Seven of 21 Type B + C tumors were partially resected, and the remainder were completely resected. All patients postoperatively reported varying improvement in their preoperative symptoms. Except for patients with NF who were disabled by other tumors, the rest of the patients resumed their normal life style. There have been no cases of symptomatic tumor recurrence. Conclusions The majority of PNSTs located at the C-2 level in these patients probably arose from the large C-2 ganglion and are limited within the dural confines or are interdural in location. In contrast to other spinal PNSTs, the location of C-2 PNSTs is in most cases posterior to the lateral mass of the atlas and axis and the atlantoaxial joint and is exposed to the posterior without any bone cover. Radical tumor resection is safe, resolution of clinical symptoms is rapid, and recurrence rates are extremely low. In a selected number of cases, bone work for tumor exposure and resection can be entirely avoided.


2010 ◽  
Vol 344 (1-2) ◽  
pp. 267-276 ◽  
Author(s):  
Janice M. Kraniak ◽  
Daochun Sun ◽  
Raymond R. Mattingly ◽  
John J. Reiners ◽  
Michael A. Tainsky

Sign in / Sign up

Export Citation Format

Share Document